ClostraBio, a biotechnology company developing next-generation probiotics, has achieved multiple significant milestones including the commercial launch of its debut product featuring Anaerostipes caccae CLB101™ and the initiation of human clinical testing. The company announced these developments alongside its upcoming participation in SupplySide Global, marking a pivotal moment in the advancement of gut health therapeutics.
Commercial Partnership with Designs for Health
The company's first commercial product has launched through Designs for Health (DFH), a leader in science-backed nutritional supplements distributed through the healthcare practitioner channel. This strategic partnership reflects ClostraBio's commitment to working with organizations that prioritize rigorous scientific validation and education in the practitioner space.
"We are thrilled to partner with Designs for Health to introduce CLB101™ to the market," said Ritu Shah, CEO of ClostraBio. "Our organizations share a deep commitment to scientific integrity and the advancement of evidence-based products. This alignment is precisely why we chose Designs for Health as our first commercial partner."
Clinical Study Initiation
ClostraBio has initiated a 48-subject clinical study evaluating Anaerostipes caccae CLB101™. The trial is designed to confirm the safety and tolerability of the company's next-generation probiotic, with exploratory endpoints regarding its potential to support gut health and intestinal barrier integrity. According to the company, the study is enrolling quickly, demonstrating both the unmet need for new dietary supplements that support gut health and immense market interest in next-generation probiotics.
"With a hypothesis-driven approach to understanding Anaerostipes caccae CLB101™'s impact on gut barrier function as well as the consumer experience, this clinical study reaffirms ClostraBio's dedication to redefining the notion of 'healthy'," said Brian Meehan, CSO of ClostraBio.
Unique Probiotic Technology
CLB101™ represents a significant advancement in probiotic technology. The strain, isolated from healthy humans, is unique and highly differentiated from legacy probiotics as a strict anaerobe with the capacity to directly produce butyrate in the lower gut. This mechanism is designed to impact gut barrier integrity, immunity, and microbiome balance. The probiotic has achieved self-affirmed GRAS status and is currently marketed in the US as a dietary supplement.
Company Background and Platform
ClostraBio leverages a science-driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. Beyond its next-generation probiotic that produces butyrate in the lower gut, the company is also developing a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations.
Industry Engagement
To promote these milestones, ClostraBio will attend SupplySide Global from October 27-30, where the team will share its progress, connect with partners, and advocate for science-driven innovation across the probiotics industry. Additionally, CEO Ritu Shah was selected as a SupplySide Global advocate in 2025, where she was featured in a video discussing the importance of the event.
